Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2005-04-18 | Mr. Herbert H. McDade, Jr. was elected to be one of our directors in 1988. He is Chairman of the Compensation Committee of the Board. Each director who is not our employee receives a quarterly fee of $3,000 and $1,000 per quarter per committee (aggregate for all committees) in which he/she is a member. |
| 2006-04-25 | Mr. McDade was a member of the Compensation Committee of the Board. |
| 2007-04-13 | Mr. Herbert H. McDade, Jr. has served as one of our directors since 1988 and was previously a member of the Compensation Committee of the Board. ... The Compensation Committee was composed of Herbert H. McDade, Jr., Jeffrey B. Davis, J. Michael Flinn and Stephen B. Howell, MD. ... The table below represents the compensation paid to our directors during the year ended December 31, 2006: Herbert H. McDade, Jr.: Fees earned or Paid in Cash ($) 17,200, Option Awards ($) 6,137, Total ($) 23,338. |
| Filing Date | Source Excerpt |
|---|---|
| 2001-04-24 | Herbert H. McDade, Jr. (74) first became a director of CytRx in 1990. ... The current members of the Audit Committee are Raymond C. Carnahan, Jr. (Chairman), Lyle A. Hohnke and Herbert H. McDade, Jr. ... The Compensation Committee's current members are Herbert H. McDade, Jr. (Chairman), Raymond C. Carnahan, Jr. and Lyle A. Hohnke. |
| 2003-09-17 | Herbert H. McDade, Jr. is a member of the Audit Committee and Compensation Committee. Messrs. Carnahan and McDade have informed the Board of Directors that they will retire from the Board of Directors, effective immediately prior to the Annual Meeting. |
| Filing Date | Source Excerpt |
|---|---|
| 2010-11-15 | Mr. McDade brings to our Board over 14 years of general management experience in the pharmaceutical industry. |
Data sourced from SEC filings. Last updated: 2025-12-06